(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 4.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Immatics Nv's revenue in 2026 is $98,555,813.On average, 13 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,598,500,581, with the lowest IMTX revenue forecast at $1,715,508,755, and the highest IMTX revenue forecast at $10,339,003,656. On average, 10 Wall Street analysts forecast IMTX's revenue for 2027 to be $6,929,502,944, with the lowest IMTX revenue forecast at $988,800,185, and the highest IMTX revenue forecast at $15,036,230,009.
In 2028, IMTX is forecast to generate $15,528,563,516 in revenue, with the lowest revenue forecast at $6,684,551,829 and the highest revenue forecast at $25,512,600,792.